智通财经APP讯，华东医药(000963.SZ)发布公告，近日，公司英国全资子公司Sinclair Pharma Limited(简称“Sinclair”)旗下一款全新专利成分的注射用羧甲基壳聚糖溶液KIO015获得欧盟MDR CE认证，取得欧盟市场上市准入资格，系全球首款且目前唯一一款创新型非动物源性壳聚糖医美注射产品。
KIO015(商品名：Kytogen ® Defend)产品获得欧盟MDR CE认证，表明该产品符合欧盟市场上市相关要求，具备欧盟市场准入资质，可在欧盟及相关海外市场开展销售。该事项不会对公司当前财务状况和经营成果产生重大影响，对公司未来业绩提升存在一定积极作用。该产品已取得欧盟MDR CE认证，尚未取得国内医疗器械注册证，目前亦未实际形成销售收入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.